Compyp an U date

March 2010

Safe Harbour

This presentation includes forward forward-looking statements looking statements.

Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations and the availability of financing.

These and other risks and uncertainties are detailed in the Compy p an 's Annual Report.

Morp y hoS s at a Glance

C o m p a n y	A i d d i b d t t " n n e p e n e n a n o c o m p a n y y f S F k t t k E h T D A X " r a n u r o c x c a n g e e c – A D R L l 1 ( B N Y M l l ) " e v e e o n T h i d R h / D i i t t " e r a p e c a n e s e a r c a g n o s c s u f i i D U K U S t t t s e g m e n s a o r s e s n u , ,
T h l e c n o o g y	L d i i H C A L l f t t " e a n g p r o p r e a r p a o r m y u , S & t d i t d t t t t " r o n g u n s p u e p a e n e s a e
T h i t e r a p e u c	O 0 C 7 t i b d b d H A L " v e r a n o y p r o g r a m s a s e o n u S t l l i i t h h i " r o n g a a n c e s w p a r m a c o m p a n e s G i i i b d f l i t t t " r o n g p r o p r e a r a n o p o r o o w y y M i l t d l t i l l " e s o n e s a n r o y a e s o n a p r o g r a m s
/ R h e s e a r c D i i t a g n o s c s	A b D S f i b l i k t t t t " e r o e c p r o a e o g r o n g m a r e u w , f I i t t i D i t i k t " n c r e a s n g p e n e r a o n o a g n o s c s m a r e

Successful Performance in 2009

	G l f 2 0 0 9 o a s o r		C S t t t r r e n a s u u
P P d t t a r n e r e	2 4 I N D " s –		6 i l i i 5 7 " p r o g r a m s n c n c ,
D i s c o v e r y	U 2 0 t t t " p o n e w p r o g r a m s a r s	1 7	F l l- i f N i t t t t " u e r m c o m m m e n r o m o v a r s
			N i f i d i i i t t t " e w n e c o u s s e a s e o p p o r u n e s
	O C M R 1 0 3 l t P h 1 " : o m p e e		D l t i t i b i l t " e v e o p m e n o r g a n z a o n u
P i t r o p r e a r y D l t e v e o p m e n	O S / M R 1 0 3 t t P h 1 b 2 " : a r a		7 1 i P h 2 1 I N D " p r o g r a m s n p r e - , ,
	U t 5 " p o n e w p r o g r a m s	3
	f € 2 0 R " e v e n u e s o a p p r o x m		N l d h i " e w e a e r s p
S S A b D t t e r o e c	f f % P i t i t l t 2 " r o m a r g n o a e a s		B i d i t i l t i h i " u r g e o n n g a g n o s c r e a o n s p s

F i i l	R f € 8 0 € 8 5 " e v e n u e s o m m -		O i d b l d i i h t t " n g o n g o u e g r e v e n u e g r o w -
n a n c a P f e r o r m a n c e	O i f i f € 8 € 1 1 t t " p e r a n g p r o o m m -		S h- f l f d R & D t " r o n g c a s o n s o n w u w

Propy p rietary Development: Strategic Considerations

Evaluation of potential acquisitions

Companies with antibodies in late preclinic/early clinic
Cancer & inflammation

The aim:St thMorphoSys's pipeline

Findings

No company under review passed final rengthen due diligence

Internal situation

place
Proprietary portfolio compares favorably to others'

Outcome

Acti ^e p rs it of Active pursuit acquisitions for proprietary portfolio mo ed from high moved priority activity to opportunistic
Remain open for inlicensing opportunities Experienced development team now in

HuCALPLATINUM: Technology p Leadership

Modular gene design & construction

HuCAL (Human Combinatorial Antibody Library)
Antibodies are fully human are
HuCAL PLATINUM launched in December 2008
Unique, built-in optimization capabilities
Robust intellectual property position

Optimization of antibodies delivers superior drug candidates

MorphoSys AG – Company Update – March 2010 © MorphoSys AG MorphoSys Page 7

Robust Intellectual Propy y ert y Protected b Core Patent Families

HuCAL Library Design and Use (~2016 expiry)
5 US patents
2 EP patents (several EU states)
2 AU patents
Pending applications: CA EP JP US
TRInucleotide Mutagenesis (JHU excl. license) (~2013 expiry)
US, EP and JP patents; pending in CA
Di lfid Di l ( Disulfide Display (C Di l ys sp ay) ( 2020 i ) ) (~2020 expiry)
US, EP, AU and JP patents
Pending applications: CA EP IL NO US
Technology Development (HuCAL PLATINUM ®)
Several applications pending
Co-exclusive access to various Dyax biologics patent families
Patent applications for antibody drug candidates
Patent filings and in-licensed patents for proprietary candidates

Current Product Pipeline

N a m e	P t a r n e r	T t a r g e	I d i i t n c a o n	D i s c o v e r y	P l i i r e c n c	P h 1 a s e	P h 3 M k t a s e a r e
Q 8 8 0 B H	N t i o a r s v	1 D K K-	C a n c e r
d. n.	C t e n o c o r	d. n.	/ I l m m n o o g u y C a n c e r
G t b a n e n e r m a u	R h o c e	β A l i d- m o y	A D
d. n.	C t e n o c o r	d. n.	f I l t i n a m m a o n
d. n.	N t i o v a r s	d. n.	d. n.				6 5 P P d d t t a r n e r e P r o g r a m s
d. n.	B r S a y e h i c e r n g	C X ( A I M N )	C a n c e r
2 7 P t d a r n e r e P r o g r a m s	V V i i a a r r o o u s s	V V i i a a r r o o u s s	V V i i a a r r o o u s s
3 1 P t d a r n e r e P r o g r a m s	V i a r o u s	V i a r o u s	V i * a r o u s
M O R 1 0 3	-	G M C S F -	R A
M O R 2 0 2	-	C D 3 8	M l t i l M l u p e y e o m a
M O R 2 0 3	-	d. n.	C a n c e r
M O R 2 0 5	-	d. n.	C a n c e r				7 P i t r o p r e a r y P r o r a m s
M O R 1 0 4	-	d. n.	I f l i t n a m m a o n				g
M O R 1 0 5	-	d. n.	I f l i t n a m m a o n
M O R 2 0 6	-	d. n.	C a n c e r	T t a r g e s r e	l l t c e n s e e y	d t c e
d. n.	O / O M R N V	d. n.	d. n.				P D P 1 r e- e r o g r a m v.

* Includes cancer, inflammatory, autoimmune, infectious, musculoskeletal & central nervous system diseases

HuCAL: Well-Established in Pharma Industr y

Partnership yp p g s: Typical Terms per Program

i i i i T T l l m e n e	M 2 0 0 4 I i i l d l, i l d i i k t t t " a n a e a n c n g e q s a e y : u u y N N b b 2 2 0 0 0 0 7 7 M j j i i " o v e m e r : a o r e x p a n s o n N b 2 0 1 7 E d b j 2 i i t t t t " o e m e r n s e c o e a r e e n s o n o p o n v : u -y x ,
N i t o v a r s p a y s …	A A € € 2 2 0 0 h h l l l l i i i i l l d d i i H C C A A L L t t " p p r o m p a e c n o o g c e n s e n c n g x y u u i l i i f t t n e r n a a o n e e s z € f A 2 0 i h d i " p p r o x m p a n r e s e a r c u n n g O € 2 0 i l ( b b i l i d j d ) 5 t t t " e r m m e s o n e s p r o a a s e v y u R l t i l l l t i d " o y a e s o n a r e s u n g r u g s
N i t t o v a r s g e s …	P f d H C A L f i 1 0 0 d i t " r e e r r e a c c e s s o u o r u s e n o v e r s c o v e r y p r o g r a m s
C d l t o e e o p m e n v - i t o p o n	S S h h d d & & f f i i ( 2 0 % 5 5 0 0 % % ) ) l l d d d d l l d d t t t t t t " a r e c o s s p r o s o n s e e c e c o e v e o p e – p r o g r a m s
E l d d c e x u	f M t i t i d i t t " o s n e c o u s s e a s e a r g e s

P t a r n e r	D i i h i S k " a c a n o y
T T i i l l i i m e n e	M h 2 0 0 6 I i i l l l i t " a r c n a a a n c e : O f f t b 2 0 0 9 E t i i t i d i " c o e r : x e c u o n o n e c o u s s e a s e d l e a
F o c s u	f D i d d d l l t t t h t i " s c o v e r y a n e e v v e e o o p p m m e e n n o e r a p e u c t i b d i i t t i t t i t d a n o e s a g a n s c e r a n a r g e s a s s o c a e f i t h h i t l- i d i t i w o s p a a c q u r e n e c o n s
D i i h i a c S k a n o y P a y s …	T i f i l i f t- " a r g e s p e c c c e n s e e e s R & D f d i f d d i " n n g o r r g s c o e r u u v y & f f f f R D d i d l t i t i " u n n g o r e v e o p m e n o n e c o u s d i l t d t h l i s e a s e r e a e e c n o o g e s M i l & l i l i d t t t " e s o n e s r o a e s o n r e s n g g r g g s y y u u
Mo ho Sy A G Co rp s mp an –	Up da Ma h 2 0 1 0 te y rc –	© Mo Mo ho ho Sy Sy A G Pa 1 3 rp rp s s g e

N a m e	P t a r n e r	T t a r g e	P h 3 a s e	M k t a r e
Q B H 8 8 0	N t i o v a r s	D K K- 1	/ 0 2 2 0 0 9 : t d i t s u y w	S t t P h 1 a r a s e h Z t i o m e a n m	/ 2 b i t i c o m n a o n l t i l l u p e m y e o m a
d. n.	C t e n o c o r	d. n.	1 0 / 2 0 0 9 : 1 1 0 0 / / 2 2 0 0 0 0 8 8 :	S P h t t a r a s e S S P P h h 2 t t t t a r a s e	2 i l n o n c o o g y i i I P F n
G b t a n e n e r u m a	R h o c e	A l i d- β m y o	2 0 0 9 T : w S 2 0 1 0 t : a	P h 1 t o a s e s u t P h 2 r a s e s c	d i l d t e s c o m p e e h d l d e u e
d. n.	C t e n o c o r	d. n.	0 6 / 2 0 0 9 :	S t t P h a r a s e	1 i i f l t i n n a m m a o n
d d. n n.	N i t o a r s v	d d. n n.	0 6 / 2 0 0 9 :	S t t P h 1 a r a s e
d. n.	B r S a e y h i c e r n g	C X ( A I M N )	1 0 / 2 0 0 9 : d j r g c o n u	S t t P h a r a s e t g a e u	1 i t h t i b d w a n o y

Potential for first P-o-C data from partnered HuCAL program
4 - 6 INDs with various partners
Roche plans to move into Ph 2 in 2010 with Gantenerumab (AD); potentially others

BHQ ( 880anti-DKK-1) – Novartis Most Advanced HuCAL Compound

The Drug

H CAL ^u I G1 tib d t ti DKK IgG1 antibody, targeting DKK-1
Overexpression of DKK-1 by myeloma cells may upset the normal balance between osteoblasts and osteoclasts
Antibody vs. DKK-1 may play a role in preventing osteolytic bone disease in multiple myeloma patients

Development

Phase 1/2 study is ongoing in the US
Preclinical studies support the hypothesis that BHQ880 promotes bone the hypothesis that BHQ880 promotes formation and thereby inhibits tumor-induced osteolytic disease
A phase 1/2 combination study in combination with Zometa/Reclast in relapsed or refractory myeloma patients has started in February 2009 or February
Novartis published some early clinical results from this program at the last ASH meeting in December 2009 in Orlando

Partnered Business: Projected HuCAL Drugs on the Market

Source: MorphoSys internal statistics & Tufts Centre for the Study of Drug Development

MOR103 is a fully human HuCAL antibody targeting GM-CSF

MOR103 blocks binding of human GM-CSF to its receptor with sub-pM affinity
Clinical material is produced using PER.C6® cell-line (Crucell/DSM)
Phase 1 successfully completed: 63 healthy volunteers double volunteers, double-blind, placebo-controlled, single ascending dose
Promising pre-clinical data for second indication

MOR103: The Opp y ortunity

T t a r g e	G M C S F i l l i l i d i R A t s c e a r m p c a e n y - f L k i d d i i t t d d l i R A t i t e u n e -m m e e a a e e a r e s n p a e n s ƒ f E l t d i i t h i t i j i t ƒ e v a e p r e s e n c e n s y n o v u m o a r r c o n s & f A t i b d i l i t i t R A i ƒ n o e s a m e o r a e s g n s s y m p o m s o n t b l i h d i l d l e s a s e a n m a m o e s
M k t a r e	\$ M k t 1 0 b > ƒ a r e n % f F t h 2 5 R A t i t d t l e w e r a n o p a e n s a e q u a e y ƒ t t d r e a e % f 5 0 T N F d t d i i t h i ƒ o -r e s p o n e r s s o p r e s p o n n g w n 2 y e a r s	i G e n u n e b l k b t o c u s e r i l t t p o e n a
I P	B d i i h U S A t t t t t r o a p a e n p r o e c o n n e S E l i l i t t d U t t i k ƒ x c u s v e c e n s e o g r a n e p a e n c o v e r n g e y f G C S t i b d i i t M F u s e s o a n o e s a g a n s - P t t l i t i i t i b d i t h l ƒ a e n a p p c a o n s c o v e r n g a n o e s e m s e v e s P t t l i t i i i d i t i ƒ a e n a p p c a o n s c o v e r n g n e w n c a o n s

MOR103 – Ph 1b/2a (MSC-1001) in Rheumatoid Arthritis – Clinical Trial Update

Trial approved in Germany, Bulgaria, The Netherlands
Study in 135 RA patients, randomized, double-blind, placebo-controlled, multiple ascending dose
Geographic mix provides access to full spectrum from biologics-pretreated to biologics-naïve RA patients
Primary outcome measures: Adverse event rate and safety profile
Secondary outcome measures: DAS28, ACR core set measures and EULAR28 response criteria, cytokines, synovitis, bone edema, pharmacokinetics, immunogenicity and patient reported outcomes up to 16 weeks
Stable regimen of concomitant RA therapy (including anti-TNFs)

	2 0 0 8	2 0 0 9	2 0 1 0	2 0 1 1	2 0 1 2
P h 1
/ P h 1 b 2 a
D A l i t a a n a y s s
i i / / F F l l P h 1 1 b b 2 2 D D t t n a a a a

MOR202: The Opp y ortunity

T t a r g e	C D 3 8 f d h f f i l l t o n o n e s r a c e o m a n m m n e c e s ; u u y u P P i i i i d d i i t t i i M M l l t t i i l l l l r m a r y n c a o n : u p e m y e o m a ƒ % f H i l d i 9 5 l t i l l d e a v y o v e r- e x p r e s s e n o m u p e m y e o m a a n ƒ l k i l l l i s o m e e u e m a c e n e s C C C C C C C C A A t t i i b b d d i i d d l l l l- k k i i l l l l i i b b A A D D D D d d ƒ n o y n u c e s c e n g y a n , t i a p o p o s s
M k t a r e	M l i l l t p e m e o m a u y : % f 1 0 h t l i l ƒ o e m a o o g c a c a n c e r s % f 1 l l ƒ o a c a n c e r s % f 2 d t h ƒ o c a n c e r e a s N t i t h i t h k t ƒ o c u r a v e e r a p e s o n e m a r e M d i i l 2 4 3 0 t h l l t i t t l l ƒ e a n s u r v v a m o n s a p a e n s e v e n u a y - , l r e a p s e	i T t a r g e n g a j m a o r u n m e d i l m e c a n e e
O h t e r I d i i t n c a o n s	L k i b i l d t e u e m a e n g e v a u a e

major unmet medical need

MOR202 –Development Plan

Manufacturing of clinical grade material completed according to plan
Prepare for Ph 1/2 in multiple myeloma in 2011 multiple in
File CTA in Q4 2010
Rationale for extended timeline of MOR202
Sh d titi fil Sharpened competitive profile
Longer chronic toxicity study to enable long-term clinical development
Competitive advantage: Tox species available (cross-reactivity to non-human primate), robust d l tlevelopment plan

	2 0 0 9	2 0 1 0	2 0 1 1
f i M t a n a c r n g u u
T i i S d t t o c x y u y
C T A P i t r e p a r a o n
C T A F i l i n g
S S / / f f P h 1 1 2 2 t t t t a r o a

Clinical Pipeline

Number of Partnered and Proprietary Programs at Year-end

Clinical Antibody Pipeline is ^a Key Value Driver

Opp j ortunities in Two Major Markets

Focus on sweet spots
e.g veterinary research
Build market-leading position from strong position today
Explore core HuCAL advantages
Drive uptake of HuCAL in diagnostic gy Drive industry
Focus on most profitable accounts

AbD Serotec –Hig g hli hts in 2010

Continue executing the strategy
Focus on specific product areas, focus on ²⁵ p p high-profit accounts
Attain market-leading positions in key areas
Intensify penetration of Dx manufacturing 18.2 y p g market
Keep investing in organization
Expand geographically
Strengthen direct sales force in Europe
Tighten distributor network
Mid- to long-term plan includes build-up of Asian sales team
Continued process to increase visibility of di ti l ti hidiagnostic relationships
Financials: Above market top-line growth, continuously improve margins

Profit & Loss Statement

I i l l i E U R n m o n	2 0 0 9	2 0 0 8
R e v e n u e s	8 1 0	1 6 7
C f G S t d l d o s o o o s o	6 7	1 7
& R D E x p e n s e s	3 9 0	2 7 6
S G & A E x p e n s e s ,	2 3 9	2 0 5
T l O i E t t o a p e r a n g x p e n s e s	6 9 6	5 5 2
P f i f i O t t r o r o m p e r a o n s	1 1 4	1 6 4
N O i I t o n- p e r a n g n c o m e	1. 6	1. 6
f i f P B T t r o e o r e a e s x	1 3 0	1 8 0
I T B f i / ( E ) t n c o m e a x e n e x p e n s e	4 1	4 8
N P f i t t e r o	9 0	1 3 2
E i S h ( d i l d ) i E U R t a r n n g s p e r a r e e n u	0 4 0	0 9 5

Differences due to rounding

I i l l i E U R n m o n	2 0 0 9	2 0 0 8
A t s s e s
C h C h E i l & M k b l t t a s a s q u v a e n s a r e a e , S i t i e c u r e s	1 3 1 5	1 3 9 7
O h C A t t t e r r r e n s s e s u	2 0 5	1 2 2
T t l N C t A t o a o n- u r r e n s s e s	5 0 5	5 3 2
T l A t t o a s s e s	2 0 6 1	2 0 3 3
L i b i l i i t a e s
T l C L i b i l i i t t t o a r r e n a e s u	2 4 3	2 7 4
T t l N C t L i b i l i t i o a o n- u r r e n a e s	7 9	1 3 9
T l S h h l d ' E i t t o a a r e o e r s q u y	1 3 9 7	1 6 2 0
i i i i T l L b l t t o a a e s	2 0 6 1	2 0 3 3

Guidance 2010

I i l l i E U R n m o n	2 0 1 0 E *	2 0 0 9 A
T l G R t o a r o p e e n e s u v u	8 9 9 3 –	8 1 0
A b D S t e r o e c	2 1 2 2 –	1 9 4.
G O i P f i t t r o p p e r a n g r o u	5 9 –	1 1 4
A b D S t O t i P f i t M i e r o e c p e r a n g r o a r g n	5 8 % –	5 %
	* Es im d b t te a nu m e rs

2010E*	2009A
$89 - 93$	81.0
$21 - 22$	19.4
$5 - 9$	11.4
$5 - 8%$	5%
Tating at a during a sea

2010

Increase of total proprietary R&D investment to € 26 – 29 million (2009: € 19.3 million)

2011 – 2012

Aiming for 10% - 20% annual revenue growth
Maintain profitability while strengthening pipeline pipeline

Shareholder Structure

Experienced Management Team

Dr. Simon E. Moroney, CEO

Prior p yg y ositions: University of Cambridge/UK, University of British Columbia/Canada, ETH Zurich/CH, ImmunoGen Inc., Associate in the Harvard Medical School, Boston/USA
Commonwealth Scholar to the University of Oxford – D. Phil. 1984
German Cross of the Order of Merit (2002), Bavarian State Medal for Outstanding Services to the Bavarian Economy (2009)

M D L CFOMr. Dave Lemus,

Joined Co in 1998 from Roche, last position: Controller and Operations Manager of 90 pharmaceutical markets
Prior positions: Group Treasurer of Lindt & Sprüngli in Zurich/CH, treasury management for Electrolux AB
B.S. (University of Maryland), M.S. (Sloan School of Management, MIT)
Certified Public Accountant (CPA) in the USA

Dr. Arndt Schottelius, CDO

Joined Morp y , , p , gy p hoSys in 2008 from Genentech Inc., SF, position: Medical Director, Immunology Development
Prior positions: Berlex Biosciences, USA; Schering, Germany; Charité University Hospital, Berlin
PhD and MD degrees from the Albert-Ludwigs-University, Freiburg/Germany
Medical studies in Germany, UK and Switzerland

Dr Marlies Sproll CSO Dr. Sproll,

Joined MorphoSys in 2000 as R&D department head, promoted to CSO in 2005
Prior positions: Vienna research facility of Boehringer Ingelheim, lab leader at Merck KGaA in Darmstadt/ Germany, involved in preclinical development of therapeutic antibodies
Ph D f th M Pl k I tit t i Tübi /G D t f N t l S i b th U i it f St tt t Ph.D. from the Max PlanckInstitute in Tübingen/Germany, Doctor of Natural Science by the University of StuttgartMorphoSys AG – Company Update – March 2010 Page 30

Goals 2010

Future Value Creation

Appendix

Sup y ervisoryBoard

Dr. Gerald MöllerChairmanM i Di t f HBM Bi V t Managing Director of BioVentures, F Di t Gl b l R h Former President Boehringer-Mannheim

Prof. Dr. Jürgen Drews Vice ChairmanFormer Director Global Research, F.Hoffmann-La Roche

Dr. Walter A. BlättlerFormer Executive Vice President Science President, CFOand Technology, ImmunoGen

Dr. Daniel Camus El i i é d F CFO, Electricitéde France, Former CFO, Aventis

Dr. Metin Colpan Supervisory Director, QIAGEN Former CEO and Founder, QIAGEN

Dr. Geoffrey Vernon Chairman, Ziggus Holding Limited Former Executive Director Rothschild Asset Management

uary 2009 Date: Jan uStudy Start
Estimated E
ents ber 2010 267 mpletion D aEnrollment: Primary Co mEstimated P
Study, Wit bination W eloma Patie ate: Novemb termination controlled, D ses of BHQ8 or Refractor er Dose-de td, Placebocated IV Dos n Relapsed o eletal-relate /II Multicent Randomized arious Repea ronic Acid in ith Prior Ske or refractory doses of BH ombination acid utcome Mea e in bone ma A Phase Ib /Adaptive, RII, Using Va With Zoled rPatients W i
Double-blind 880 in Comb ry Myeloma ents will rec um dose of 2 herapy and eletal-related d Event yeloma pati eo a maxim uard chemot hmultiple m yHQ880 (up t owith stand aRelapsed oescalating dmg/kg) in c ozoledronic a
ion and for me to first sk esures: Tim earkers for b oPrimary O uand chang e
Phase bination ^aceive 20 d event mation y and cs of ects of mation, . hronic safet yated-dose nding kineti cdynamic eff eof bone for mearticipants one resorpt cute and ch e and repea genicity; bin ; pharmacod al markers o um and urin ecruiting pa ^0741377 Measures: a c single-dos ees; immuno gex in serum ;g biochemic aolism in ser uOutcome Mof BHQ880; inetic profil eQ880 compl ey measurin gand metab oSecondary tolerability opharmacok DKK1/BH QBHQ880 b yresorption,
USA, Austr aLocations: U
alia currently r es study is cStatus: Thi s
tifier: NCT0 0ls.gov Iden tClinicalTria

ken from ormation check Information ta k

For update info

6cember 2006e-ascending rt Date: Dec Study Star
t: 60 Enrollment
Doubleigate the namics of nts ndomized, D dy to Invest harmacodyn n AD Patien g Dose, Ran l-group Stud etics and Ph us Infusion i formation checkose Study o led, Paralle harmacokine g Intravenou nter, Multiple ebo-control erability, Ph 32 Following A Multi-cen blind, Plac Safety, Tol RO490983
ved either 7 doses sease receiv r a total of 7 zheimer Dis infusion for moderate Alz intravenous with mild to m placebo by i Patients w R1450 or p
rs, vital y parameter 0 in plasma s, laboratory ers of R1450 asures: AEs ic paramete utcome Mea armacokinet Primary Ou signs. Pha
al efficacy rkers, clinica CSF biomar Measures: C y Outcome M s. Secondary parameters
United weden and U herlands, Sw Israel, Neth Denmark , Locations: Kingdom
mpleted. as been com is study ha Status: Th
00531804 ntifier: NCT0 als.gov Iden ClinicalTria

kaken from Information ta For update inf

i i I t t t n s o n u	C t t o n a c
C b k o m m e r a n z	M M D i l W d f f r r. a n e e n o r
C d i t S i r e u s s e	D Y i A l- W k l r. a s r a e e
D h B k t e u s c e a n	M H l B l r. o g e r u m
D Z B k a n	D E l K r. m a r r a u s
E i I i i l S i t t t t q u n e n s u o n a e r v c e s	D M i P i k t r. a r n o s s e n e
H l e v e a	M L A O t t M D P h D r. u c e n, ,
K & C e m p e n o.	M S h i S i / M O I b d r. a c n o n r. s c a r z e o u
L d b k B B d d W W ü ü t t t t b b a n e s a n a a e e n n- r r e e m m e e r r g g	D D H F h r r. a n n s r o n m e y e r
M I D A S R h e s e a r c	M T h S h i l r. o m a s c e s s e
C N d o m u r a o e	G D W d r. a r y a a n e r s
S l. O h i a p p e n e m	D C h i i P t t r. r s a n e e r
S G S i t i e c u r e s	M R d l h B r. u o p e e s s e r v e
W L B A G t e s	D C l i T h r. o r n e a o m a s

Corporate Calendar 2010

Mar 2-4, 2010 Credit Suisse Global Healthcare Conference, London, UK Mar 23, 2010 Kempen Life Sciences Conference, Brussels, Belgium A 28 2010 Apr 28, P bli ti f Th M th ' R t 2010 Publication of Three Months' Report

Thank You.

www.morphosys.com

Dr. Simon Moroney

Chief Executive Officer

Phone +49 (0)89 / 899 27-311 ( ) ( ) Fax +49 (0)89 / 899 27-5311 Email [email protected]

Dr. Claudia Gutjahr-Löser Head of Corporate Communications & IR

Phone +49 (0)89 / 899 27-122 Fax +49 (0)89 / 899 27-5122 Email [email protected]